Nrg-Gi004- Colorectal Cancer Metastatic Dmmr Immuno-Therapy (Commit) Study: A Randomized Phase III Study Of Mfolfox6/Bevacizumab Combination Chemotherapy With Or Without Atezolizumab Or Atexolizumab Monotherapy In The First-Line Treatment Of Patients With
Posted Date: May 15, 2019
- Investigator: Jordan Kharofa
- Specialties: Cancer, Colorectal Cancer, Oncology
- Type of Study: Drug
The goal of this study is to determine the efficacy, based on progression free survival, of mFOLFOX6/bevacizumab plus atezolizumab and atezolizumab as compared to mFOLFOX6/bevacizumab
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have Colorectal Cancer, Age 18 Or Older, Nonpregnant, No Uncontrolled High Bp, No Other Malignancies Or Active Infections.
Keywords:
Colorectal Cancer, Gastrointestinal, Phase Iii, S1610
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com